STONY BROOK, NY--(Marketwired - February 09, 2015) - Applied DNA Sciences, Inc. (NASDAQ: APDN), (Twitter: @APDN), a provider of DNA-based anti-counterfeiting technology, supply chain and product authentication solutions, announced today the launch of an On-Site DNA Authentication Program (On-Site) in response to the market need to provide faster reporting of DNA authentication at every step of the cotton textile supply chain, with the goal of ensuring quality assurance, controls and sourcing of raw materials or greige goods, prior to conversion into finished goods.

The patent-pending, On-Site Program includes the provision of a desktop-size PCR (Polymerase Chain Reaction) machine with consumables for testing, complete with supporting software, on-site training, guidance on chain-of-custody protocols, and online customer service support. APDN will consult with its licensees and its supply chain partners to ensure seamless program implementation.

Potential licensees will benefit from the program by having the On-Site device located at their facility, with the ability to test a large volume of samples from different lots or batches, of raw fiber, yarn or fabric, before they are converted into finished goods. As part of the program, APDN will receive retain samples from Licensees to enable full forensic evaluation and authentication whenever required.

Dr. Mike Hogan, VP of Life Sciences, stated, "We are very excited to offer this turn-key solution that allows for both fiberTyping® and SigNature® T authentication of greige goods on site. Higher volume of testing translates to a higher degree of confidence in the authenticity of the source material."

This program will enable the on-site testing of unprocessed fiber, yarn or fabric (greige goods) by anyone in the cotton textile supply chain, including growers, ginners, spinners, manufacturers, logistics partners, brand owners, retailers and government agencies. Forensic authentication of the relevant DNA on site will help ensure that companies are compliant with international or in-country label laws.

The On-Site DNA Authentication platform complements the company's multi-modal screening platform that was announced last week. The former provides DNA-based proof of origin or authenticity, while the latter enables rapid screening with higher level of assurances than any visual inspection. The On-Site DNA Authentication Platform will be integrated with the company's service platform for full forensic assessment of its DNA markers, including Certificates of DNA Authentication (CODAs) and expert witnessing for court cases.

Dr. James Hayward, President and CEO of APDN, commented: "This is a development of historic importance, as we believe we are the first and only company to place forensic authentication in the hands of our customers and partners. If I were a brand owner, I would want to ensure that my products are never compromised. The transparency this program offers will allow brand owners, in collaboration with the textile manufacturers and suppliers, to deliver on their promise to the consumer with confidence."

The company expects to roll out on-site DNA authentication systematically to other industry verticals, including Cash and Valuables in Transit (CViT), pharmaceutics, print media, industrial materials and others.

About Applied DNA Sciences
We make life real and safe by providing botanical-DNA based security and authentication solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion. SigNature® DNA describes the platform ingredient that is at the heart of all of our security and authentication solutions. SigNature DNA is at the core of a family of uncopyable products such as DNAnet®, our anti-theft product, SigNature® T, targeted toward textiles, and digitalDNA®, providing powerful track and trace. All provide a forensic chain of evidence and can be used to prosecute perpetrators.

Applied DNA Sciences' common stock is listed on NASDAQ under the symbol APDN, and its warrants are listed under the symbol APDNW.  

Forward-Looking Statement
The statements made by APDN in this press release may be "forward-looking" in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe APDN's future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from those projected due to our short operating history, limited financial resources, limited market acceptance, market competition and various other factors detailed from time to time in APDN's SEC reports and filings, including our Annual Report on Form 10-K filed on December 15, 2014, which are available at APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.

Contact Information:

investor contact:
Debbie Bailey

media contact:
Enrique Briz
Dian Griesel Int'l.

program contact:
MeiLin Wan

twitter: @APDN